AstraZeneca’s Enhertu approved for NHS use in England
AstraZeneca and Daiichi Sankyo said their breast cancer treatment Enhertu has been approved for use in England’s state-run healthcare system, expanding access to a drug available in Scotland since 2023.
AstraZeneca LSE:AZN and Daiichi Sankyo TSE:4568 said on Thursday that their breast cancer treatment Enhertu has been approved for use in England’s state-run healthcare system, widening access to the drug after it has been available in Scotland since 2023. The companies said they will now seek approval for acc…